Stephens Reiterates “Overweight” Rating for MaxCyte (NASDAQ:MXCT)

Stephens reaffirmed their overweight rating on shares of MaxCyte (NASDAQ:MXCT) in a research report sent to investors on Tuesday, Benzinga reports. They currently have a $11.00 price target on the stock.

Several other analysts also recently commented on MXCT. BTIG Research dropped their price objective on shares of MaxCyte from $10.00 to $8.00 and set a buy rating on the stock in a report on Wednesday, March 13th. William Blair reaffirmed an outperform rating on shares of MaxCyte in a report on Wednesday, March 13th.

MaxCyte Trading Down 4.0 %

NASDAQ:MXCT opened at $3.80 on Tuesday. The company has a market cap of $396.70 million, a PE ratio of -10.27 and a beta of 1.34. MaxCyte has a twelve month low of $2.45 and a twelve month high of $5.55. The company’s 50 day moving average is $4.27 and its two-hundred day moving average is $4.32.

MaxCyte (NASDAQ:MXCT) last released its earnings results on Tuesday, March 12th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.05. The company had revenue of $15.67 million for the quarter, compared to the consensus estimate of $15.60 million. MaxCyte had a negative net margin of 91.85% and a negative return on equity of 15.90%. As a group, analysts expect that MaxCyte will post -0.53 EPS for the current fiscal year.

Insider Activity

In related news, Director John Joseph Johnston sold 5,000 shares of the business’s stock in a transaction on Friday, January 26th. The shares were sold at an average price of $5.12, for a total value of $25,600.00. Following the completion of the transaction, the director now directly owns 120,583 shares in the company, valued at approximately $617,384.96. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 6.00% of the company’s stock.

Hedge Funds Weigh In On MaxCyte

Large investors have recently made changes to their positions in the company. PNC Financial Services Group Inc. acquired a new position in shares of MaxCyte in the 4th quarter valued at $29,000. Victory Capital Management Inc. acquired a new position in shares of MaxCyte in the 3rd quarter valued at $31,000. Johnson Investment Counsel Inc. acquired a new position in shares of MaxCyte in the 3rd quarter valued at $34,000. Aigen Investment Management LP acquired a new position in shares of MaxCyte in the 3rd quarter valued at $44,000. Finally, Nisa Investment Advisors LLC raised its position in MaxCyte by 47,100.0% during the fourth quarter. Nisa Investment Advisors LLC now owns 11,800 shares of the company’s stock worth $55,000 after acquiring an additional 11,775 shares during the period. 68.81% of the stock is currently owned by institutional investors and hedge funds.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.